Moteur de recherche d’entreprises européennes
Financement de l’UE (6 026 455 €) : Dispositifs PLAsmonic ULTRAsensibles pour le diagnostic précoce de la CAncer Hor 01/05/2015 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Dispositifs PLAsmonic ULTRAsensibles pour le diagnostic précoce de la CAncer
Cancer biomarkers circulating in body fluids have been shown to reflect the pathological process and for this reason can be used for cancer diagnosis, prognosis and choice for therapeutic interventions. It is proven that their detection is a key to new minimal-invasive detection approaches. However, barriers to wide spread use of similar approaches are lack of test sensitivity, specificity and limited availability of low cost detection platforms. This project is focused at developing a compact plasmonic-based device with integrated microfluidic circuit and functionalized nanostructures for the detection of DNA, microRNA and tumor autoantibodies cancer biomarkers. The aim is to detect cancer biomarkers circulating in blood with improvement in sensitivity of factor up to 1000, reduction in cost of platform of factor ranging from 2 to 4 compared to today’s available techniques and analysis time less than 60 minutes. The proposed detection approache will provide ultrasensitive detection of biomolecular systems with no need for complex sample chemical modifications thus allowing direct and simple assays to be performed. Within the project a bimodal industrial prototype will be developed integrating novel surface plasmon resonance imaging and plasmon-enhanced fluorescence sensing technologies, respectively. Automated fabrication processes suitable for low cost mass production will be developed and applied to produce disposable integrated chips. Prototype will be specifically fabricated for early diagnosis and prognosis of colorectal cancer. The team includes partners holding cross-disciplinary competencies needed to achieve the proposed results, including two of the first five plasmon resonance groups in the world, the inventor of surface plasmon microscopy – also known as surface plasmon resonance imaging- and plasmon-enhanced fluorescence spectroscopy, and full European value chain including disposable chip and readout platforms design, development and manufacturing.
| AIT Austrian Institute OF Technology GmbH | 972 709 € |
| Amires s.r.o. | 159 750 € |
| Future Diagnostics Solutions B.V. | 524 375 € |
| Ginolis AB | 0,00 € |
| Ginolis Oy | 403 125 € |
| Horiba ABX SAS | 0,00 € |
| Horiba France SAS | 646 923 € |
| Istituti Fisioterapici Ospitalieri | 407 375 € |
| Istituto Nazionale Di Biostrutture E Biosistemi | 833 488 € |
| Scriba Nanotecnologie Srl | 270 250 € |
| Seibersdorf Labor GmbH | 0,00 € |
| Teknologian Tutkimuskeskus VTT Oy | 630 536 € |
| Universita Degli Studi Di Catania | 0,00 € |
| Universita Degli Studi Di Ferrara | 213 750 € |
| Universita Degli Studi Di Firenze | 0,00 € |
| Universita Degli Studi Di Parma | 0,00 € |
| Universitaet Siegen | 307 300 € |
| Universiteit Twente | 343 750 € |
| Ustav Fotoniky A Elektroniky AV CR V.V.I. | 313 125 € |
https://cordis.europa.eu/project/id/633937
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
